FORMULATION & EVALUATION OF CEFUROXIME ORAL SUSPENSION

The bitter taste associated with certain drugs, such as Cefuroxime Axetil, remains a significant challenge in the pharmaceutical industry, particularly concerning pediatric patient populations. The study demonstrates that inclusion complex formation with beta-cyclodextrin is a highly effective, cost-efficient, and straightforward method for taste masking. The encapsulation of the drug within the hydrophobic core of cyclodextrin proves successful in reducing the solubility of the drug in saliva, ultimately improving patient compliance. The anticipated separation of the complex within the gastric environment ensures controlled drug release, enhancing absorption from the upper part of the intestine. This complexation method, with its simplicity and confirmed efficacy through DSC analysis, presents a promising solution for addressing the bitter taste of drugs in oral pharmaceutical formulations. The thorough scrutiny of formulation parameters and the validation through DSC data contribute to the robustness and reliability of this taste masking approach in the development of pharmaceutical products for pediatric use.